Further studies revealed that anti-CD19 CAR-NKT cells are more effective than anti-CD19 CAR-T cells against CD1d-expressing lymphomas in vitro and in vivo, as they can eliminate CD1d + tumor cells by dual targeting of CD19 and CD1d on target cells, suggesting that anti-CD19 CAR-NKT cells may provide better therapeutic outcomes than traditional CAR-T cells in these tumors types [147]. Here, CD1D is linked to lymphoma.